Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 11, 2014, Pages 1285-1292

  Antoniu, Sabina Antonela ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

5 lipoxygenase activating protein; Airways; Asthma; Chronic obstructive pulmonary disease; Inflammation; Internal medicine

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; AM 679; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; BRP 7; FIBOFLAPON; UNCLASSIFIED DRUG;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; PATHOGENESIS; PEAK EXPIRATORY FLOW; PNEUMONIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; ANIMAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS; 5-LIPOXYGENASE-ACTIVATING PROTEINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84911492077     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.945425     Document Type: Review

References (47)

1. Gagnon P, Guenette JA, Langer D, et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014;9:187-201
2. Hall S, Agrawal DK. Key mediators in the immunopathogenesis of allergic asthma. Int Immunopharmacol 2014. [Epub ahead of print]
3. Postma DS, Reddel HK, Ten Hacken NHT, Van Den Berge M. Asthma and chronic obstructive pulmonary disease: similarities and differences. Clin Chest Med 2014;35(1):143-56
4. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 2014;35(1):71-86
5. Montuschi P, Santini G, Valente S, et al. Liquid chromatography - mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases. J Chromatogr B Analyt Technol Biomed Life Sci 2014;964:12-25
6. Montuschi P. LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877(13):1272-80
7. Montuschi P, Mondino C, Koch P, et al. Effects of montelukast treatment and withdrawal on fractional exhaled nitric oxide and lung function in children with asthma. Chest 2007;132(6):1876-81
8. Montuschi P, Mondino C, Koch P, et al. Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J Allergy Clin Immunol 2006;118(2):347-53
9. Steinhilber D, Hofmann B. Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin Pharmacol Toxicol 2014;114(1):70-7
10. Fanning LB, Boyce JA. Lipid mediators and allergic diseases. Ann Allergy Asthma Immunol 2013;111(3):155-62
11. Montuschi P, Sala A, Dahlén S-E, Folco G. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today 2007;12(9-10):404-12
12. Okunishi K, Peters-Golden M. Leukotrienes and airway inflammation. Biochim Biophys Acta 2011;1810(11):1096-102
13. James AJ, Penrose JF, Cazaly AM, et al. Human bronchial fibroblasts express the 5-lipoxygenase pathway. Respir Res 2006;7:102
14. Newcomer ME, Gilbert NC. Location, location, location: compartmentalization of early events in leukotriene biosynthesis. J Biol Chem 2010;285(33):25109-14
15. Prevention GSFaMA. GINA Report. GINA Report 2013
16. Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013;22(1):92-100
17. Antoniu SA. Roflumilast as add-on therapy to conventional inhalers in COPD: a cost-effectiveness analysis. J Comp Eff Res 2012;1(4):315-17
18. Antoniu SA. New therapeutic options in the management of COPD - focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2011;6:147-55
19. Chu SJ, Tang LO, Watney E, et al. In situ amplification of 5-lipoxygenase and 5-lipoxygenase-activating protein in allergic airway inflammation and inhibition by leukotriene blockade. J Immunol 2000;165(8):4640-8
20. Santus P, Sola A, Carlucci P, et al. Lipid peroxidation and 5-lipoxygenase activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171(8):838-43
21. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003;58(7):585-8
22. Montuschi P, Macagno F, Parente P, et al. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax 2005;60(10):827-33
23. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162(3):1175-7
24. Woods JW, Evans JF, Ethier D, et al. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 1993;178(6):1935-46
25. Evans DJ, Barnes PJ, Spaethe SM, et al. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996;51(12):1178-84
26. Stock NS, Bain G, Zunic J, et al. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. J Med Chem 2011;54(23):8013-29
27. Lorrain DS, Bain G, Correa LD, et al. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. Eur J Pharmacol 2010;640(1-3):211-18
28. Broadhead Ar CC, Correa L, et al. The 5-lipoxygenase-activating protein (flap) inhibitor Gsk2190915, reduces cigarette smoke-induced pulmonary inflammation in the mouse. Am J Respir Crit Care Med 2011;183:A3091
29. Bain G, King CD, Schaab K, et al. Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor. Br J Clin Pharmacol 2013;75(3):779-90
30. Kent SE, Boyce M, Diamant Z, et al. The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma. Clin Exp Allergy 2013;43(2):177-86
31. Snowise NG, Clements D, Ho S-Y, Follows RMA. Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma. Curr Med Res Opin 2013;29(12):1663-74
32. Singh D, Boyce M, Norris V, et al. Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose-response study. Int J Gen Med 2013;6:897-903
33. Follows R, Snowise N, Ho S-Y, et al. Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study. Respir Res 2013;14(1):54
34. Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily. 2014. Available from: http://clinicaltrial.gov/ct2/show/NCT01147744
35. Koeberle A, Siemoneit U, Northoff H, et al. MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation. Eur J Pharmacol 2009;608(1-3):84-90
36. Sforcin JM, Nunes GA, Missima F, et al. Effect of a leukotriene inhibitor (MK886) on nitric oxide and hydrogen peroxide production by macrophages of acutely and chronically stressed mice. J Pharm Pharmacol 2007;59(9):1249-54
37. Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 2000;161(6):1881-6
38. Lee E, Lindo T, Jackson N, et al. Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am J Respir Crit Care Med 1999;160(6):2079-85
39. Woo JS, Kim SM, Jeong CH, et al. Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP- and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma. Biochem Biophys Res Commun 2013;431(2):354-9
40. Cheraim AB, Xavier-Elsas P, De Oliveira SHP, et al. Leukotriene B4 is essential for selective eosinophil recruitment following allergen challenge of CD4+ cells in a model of chronic eosinophilic inflammation. Life Sci 2008;83(5-6):214-22
41. Stock N, Baccei C, Bain G, et al. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin- 2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679) - a potent FLAP inhibitor. Bioorg Med Chem Lett 2010;20(1):213-17
42. Musiyenko A, Correa L, Stock N, et al. A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye. Clin Vaccine Immunol 2009;16(11):1654-9
43. Pergola C, Gerstmeier J, Monch B, et al. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP). Br J Pharmacol 2014;171(12):3051-64
44. Hamilton AL, Watson RM, Wyile G, O'byrne PM. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 1997;52(4):348-54
45. Fischer AR, Rosenberg MA, Roth M, et al. Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air. Thorax 1997;52(12):1074-7
46. Dahlen B, Kumlin M, Ihre E, et al. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax 1997;52(4):342-7
47. Bain G, King CD, Rewolinski M, et al. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP). Clin Pharmacol Ther 2010;87(4):437-44